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Abstract
Similar to pharmaceutical products, medical devices play an
increasingly important role in healthcare worldwide by con-
tributing substantially to the prevention, diagnosis and
treatment of diseases. From the patent law perspective
both, pharmaceutical products and a medical apparatus,
product or device can be patented if they meet the patenta-
bility requirements, which are novelty, inventiveness and
entail industrial applicability. However, regulatory issues also
impact on the whole cycle of the innovation. At a European
level, enhancing competitiveness while ensuring public
health and safety is one of the key objectives of the Europe-
an Commission. This article undertakes literature review of
the current and incoming regulatory framework governing
medical devices with the aim of highlighting how these
major changes would affect the industry at issue. The analy-
sis is made in the framework of an on-going research work
aimed to determine whether SPCs are needed for promoting
innovation in the medical devices industry. A thorough anal-
ysis the aforementioned factors affecting medical device’s
industry will allow the policymakers to understand the root
cause of any optimal patent term and find appropriate
solutions.
Keywords: Medical Device Directive, Medical Device Regu-
lation, regulatory, European Union, reform, innovation,
SPCs, policy
1 The Need for a Regulatory
Framework for Healthcare
Products
Medicines and medical devices have been in existence
for centuries. According to the literature, there is evi-
dence that scalpels, slings, splints, crutches and other
medical devices were used as long ago as 7000 BCE by
the Egyptians.
Neither drugs nor medical devices are ordinary consum-
er products. In most instances, consumers are not in a
* Magali Contardi, PhD candidate; Avvocato (Italian Attorney at Law).
position to make decisions about when to use them,
which to use, how to use them and how to weigh poten-
tial benefits against risks as no medicine or device is
completely safe. While the concept of ensuring their
quality has evolved gradually over time, the modern
health products regulation started only after break-
through progress in the nineteenth century, especially in
chemistry, physiology and pharmacology.
Historically, countries have tended to introduce regula-
tion or tighten existing regulation only when forced to
do so by a public outcry over an unexpected and unfor-
tunate event. First and foremost, concerns raised over
adulterated foods triggered the creation of the Federal
Drug Authority (hereinafter ‘FDA’) in 1906. Although
it was not known by its present name until 1930, FDA’s
modern regulatory functions began with the approval of
the 1906 Pure Food and Drugs Act, a law that prohibi-
ted interstate commerce in adulterated and misbranded
food and drugs.1 In 1937, the death of over 100 Ameri-
cans who had taken a cough mixture containing an anti-
freeze-type chemical facilitated the introduction of pre-
market testing to their medicinal regulatory require-
ments. Later, in the 1960s, with the thalidomide inci-
dent, a tranquilliser and sleeping pills that caused pho-
comelia in newly born children as a side effect,2 the
international community has shared consensus that
drug, medical technologies and products used in patient
care must be subject to stricter regulation than other
consumer goods. In fact, however, regulation for medi-
cal devices started relatively late, triggered mainly by a
major public concern in the 1960s and 1970s regarding
the risk of micro-shock from an electrical current via
devices connected to patients.3 During the 1970s and
1980s, demand for stronger regulatory legislation arose
1. W.F. Janssen, ‘The Story of the Laws Behind the Labels’, 15 FDA Con-
sumer, 32-45 (1981), available at: https://www.fda.gov/downloads/
AboutFDA/History/FOrgsHistory/EvolvingPowers/UCM593437.pdf.
2. Resulting in the shortening or absence of limbs. Helix Magazine, The
Thalidomide Tragedy: Lessons for Drug Safety and Regulation (28 July
2009), available at: https://helix.northwestern.edu/article/thalidomide-
tragedy-lessons-drug-safety-and-regulation (last visited 7 April 2019).
3. M. Cheng, ‘HNP brief. No. 8: An Overview of Medical Device Policy
and Regulation’, World Bank, February 2007 http://www-
wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/
2007/03/02/000310607_20070302113845/Rendered/PDF/
388190HNPBrief801PUBLIC1.pdf (last visited 7 April 2019).
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from serious effects caused by intrauterine contraceptive
devices (the Dalkon shield and the Copper-7 device)
and several brands of tampons. Beginning in the 1970s,
countries with a strong medical device industry4 initi-
ated the process of either developing or strengthening
their regulatory systems.5
While in most countries around the world the need for
regulation arose primarily to enable patients’ access to
high-quality, safe and effective medical devices, and
avoid access to products that are unsafe,6 in Europe the
regulatory environment became more stringent mainly
to enhance the cohesion of the Single Internal European
Market.
Indeed, with the signature of the Treaty of Rome in
19577 (hereinafter ‘EC’ Treaty) a Single Market for the
European Union was created, with the aim of, among
others, removing barriers to trade within the European
Community (EU) Member States. In line with such an
objective, Article 30 of the EC Treaty8 forbids ‘qualita-
tive restrictions on imports and all measures having
equivalent effect between Member States’, although
derogations are allowed, based, inter alia, on grounds of
protection of health and life of humans, animals or
plants. Therefore, this can only confirm Altenstetter’s
arguments:9 in Europe, regulation of the medical device
sector in a harmonised manner would not only ensure
patients’ access to high-quality, safe and effective medi-
cal devices but would also contribute to the smooth
functioning of the internal European market, enhancing
competitiveness of the Eurozone.
2 The Medical Device Industry
at a Glance
Pharmaceuticals and medical devices are similar in cer-
tain respects: both are health technologies; both can be
used to diagnose, treat, alleviate and cure disease; both
4. Among them Canada, United States, Japan and the European Union.
These countries nowadays account for close to eighty percent of the
medical devices market share. Medtech Europe, Facts and Figures 2018,
available at: https://www.medtecheurope.org/wp-content/uploads/
2018/06/MedTech-Europe_FactsFigures2018_FINAL_1.pdf (last visited
4 April 2019).
5. The role of medical devices and equipment in contemporary healthcare
systems and services. World Health Organization. Technical discussion
document for the Fifty-third Regional Committee for the Eastern Medi-
terranean, Agenda item 7 (b), (EM/RC53/Tech.Disc.2), (2006).
6. For instance, this idea was institutionalised in the Medical Device
Amendments of 1976 in the United States, manifested in the 2002 Jap-
anese Pharmaceutical Affairs Law as amended in 2005 and partially
incorporated in the EU legislation of 1987 creating the single European
market, the legal foundation of the medical device framework initiated
in the 1990s. C. Altenstetter, ‘Medical Device Regulation in the Europe-
an Union, Japan and the United States. Commonalities, Differences and
Challenges’, 25 Innovation, 362-88 (2012).
7. Treaty Establishing the European Economic Community (ECC), signed
on 25 March 1957 and applied from 1 January 1958, available at:
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISSUM
%3Axy0023 (last visited 11 March 2019).
8. EC Treaty, Arts. 30-36, Ibid.
9. Altenstetter, above n. 6.
require regulatory oversight and a post-market surveil-
lance system; both have intellectual property issues;
both need a supply chain; and both have become an
integral part of modern healthcare.
The pharmaceutical industry has been economically rel-
evant in the European Union for quite some time; the
world pharmaceutical market was worth €934.8 million
in 2017. By contrast, the medical device industry has
only recently become more visible, reaching a global
market value of €360.8 billion10 for the same period.
Yet, according to the European Commission, the medi-
cal device sector has turned increasingly important for
the healthcare of the European Union’s citizens, with a
market estimated at roughly €110 billion11 in 2016.
The United States is the largest market for both phar-
maceuticals and medical devices, which are estimated to
be 48.1% and 43% of the global market, respectively.
The European pharmaceutical and medical devices mar-
ket is the second largest, representing 22.2 % and 29%
of the global market, respectively. According to the
Medical Devices Sectoral Overview – Galway City and
County Economic and Industrial Baseline Study,12 the
leading European Union medical devices markets are
Germany, France, the United Kingdom, Italy and
Spain. These top five countries make up 71% of the
European medical devices market, while Germany and
France together make up nearly half.
The medical devices industry is highly fragmented, con-
sisting of small niche markets with only a few products.
According to the European Medical Device Industry
Trade Association (hereinafter ‘EUCOMED’), of the
approximately 27,000 medical technology companies in
Europe, 95% are classified as small and medium-sized
companies. The highest percentage of these is based in
Germany, followed by the United Kingdom. After the
United Kingdom, the leaders in terms of the number of
companies are Italy, Switzerland, France and Spain.
The industry includes companies such as Siemens,
Hewlett-Packard, Philips and, GE-Healthcare, which
operate mainly in electrical-medical equipment, as well
as companies such as Boston Scientific and Medtronic,
which dominate the implantable device sector.13
Owing to their intensive research,14 the protection of
intellectual property is crucial to preserve the competi-
tiveness of these industries. Indeed, the lack of enforce-
10. Worldwide Medical Devices Forecast 2020 Report, available at: http://
info.evaluategroup.com/rs/607-YGS-364/images/mtwp15.pdf (last vis-
ited 9 April 2019).
11. Medtech Europe, The European Medical Technology Industry in Figures
2018, available at: https://www.medtecheurope.org/wp-content/
uploads/2018/06/MedTech-Europe_FactsFigures2018_FINAL_1.pdf
(last visited 8 April 2019).
12. J. Cunningham, B. Dolan, D. Kelly, C. Young. Medical Device Sectoral
Overview, Galway City and County Economic and Industrial Baseline
Study (2015).
13. MDDI Ranking.
14. According to the EU Industrial R&D Investment Scoreboard 2018, the
R&D shares of the health sector – comprising pharmaceuticals and med-
ical devices – accounts for 22% of the EU R&D expenditure, available
at: https://ec.europa.eu/info/news/2018-industrial-rd-scoreboard-eu-
companies-increase-research-investment-amidst-global-technological-
race-2018-dec-17_en (last visited 6 March 2019).
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ment of Intellectual Property Rights creates disincen-
tives for innovation and prevents companies from
recouping their investments in R&D. In 2017, medical
technology ranked first in patent applications at the
European Patent Office,15 with 13,134 applications
(6.2 % +), most of which were filed by applicants from
the United States (37%), Japan (9%) and, among the
European countries, Germany (10%), France (5%),
United Kingdom (3%), Italy and Spain. In comparison,
around 5,534 applications were filed in the same period
in the pharmaceutical field, most of them by applicants
from the United States, followed by Germany, France
and Switzerland.
Any discussion about the regulatory issues around
health products in Europe may only start meaningfully
if there is clarity about the terms ‘medicinal products’
and ‘medical devices’. Medicinal products refer general-
ly to any substance or combination of substances that
may be administered to human beings or animals with a
view to making a medical diagnosis or to restoring, cor-
recting or modifying physiological functions in human
beings or animals.16 A product is classified as a medici-
nal product on the basis of either its presentation and
therapeutic purpose or the type of action exerted by the
substance.17 By contrast, medical devices overall refer to
any apparatus, software, material or other similar or
related item intended to be used in the diagnosis, pre-
vention, monitoring, treatment or alleviation of a disease
or injury and that does not achieve its principal intend-
ed action in or on the human body by pharmacological,
immunological or metabolic means.18
The foregoing shows that the difference between medic-
inal products and medical devices lies substantially in
the interpretation of the main concepts that define
them, namely therapeutic effect and mechanism of
action.19 Both medical devices and pharmaceuticals (or,
more precisely, medicinal products) share the common
property of exerting a therapeutic effect, although they
are different in regard to their mechanism of action.
Medicinal products achieve their principal intended
action in or on human bodies by pharmacological,
immunological or metabolic means. In contrast, a medi-
cal device does not achieve its principal intended action
15. European Patent Office, Annual Reports and Statistics (2017), available
at: https://www.epo.org/about-us/annual-reports-statistics/statistics.
html#filings (last visited 15 January 2019).
16. Art. 1(2) of Directive 2001/83/EC of the European Parliament and of
the Council of 6 November 2001 on the Community code relating to
medicinal products for human use. Official Journal of the European
Communities No. L-311/67 of 28 November (2001).
17. The definition of medicinal product was issued originally in Directive
65/65/ECC of 26 January 1965 on the approximation of provisions laid
down by law, regulation or administrative action relating to proprietary
medicinal products and referred only to the purpose of the product.
Official Journal of the European Communities no. P-022 of 9 February
(1965).
18. European Union Directive 93/42/ECC concerning medical devices of
14 June 1992. Official Journal of the European Communities No.
L-169 of 12 July (1993).
19. M. Racchi, S. Govoni, A. Lucchelli, L. Capone, E. Giovagnoni, ‘Insights
into the Definition of Terms in European Medical Device Regulation’, 13
Expert Review of Medical Devices, 907-17, (2016).
in the human body by pharmacological, immunological
or metabolic means but may be assisted in its function
by such means. Differences such as these justify distinct
regulatory regimes.
Developing a new medicinal product or a new use of an
existing drug takes a long time; safety and efficacy must
be proven before it can be brought to market. This pro-
cess is enormously expensive because of laboratory, ani-
mal and various human trials, as well as high costs of tri-
als needed for regulatory approval.20 The most recent
analysis by the Tufts Center for the Study of Drug
Development estimated the average cost of developing
and gaining marketing approval for a new drug at
$2,6 bn., based on estimated average out-of-pocket costs
($1,395 bn.) and the expected returns that investors
forego while a drug is in development (1,163 bn.).21 By
contrast, the dimension, complexity and function of
medical devices vary significantly. Hurdles to proving
safety and efficacy differ according to the risk level asso-
ciated with the use of the medical device: more complex
and more invasive devices generally require substantial
clinical trials and assessment before approval for market
launch is granted, whereas non-invasive and low-risk
devices face minimal regulatory hurdles before they can
be marketed.
Interestingly, most of the earlier comparative studies on
medical device regulatory framework concluded that
Europe has been granting faster access to medical tech-
nology (e.g. compared with the United States). In a
report22 John Wilkinson, chief executive of
EUCOMED, commented: ‘The current European
Union regulatory system makes innovative medical
technology available to people the fastest in the world
while ensuring the highest safety standards.’ In line with
it, Migliore23 argued that many independent studies
showed that the path to obtaining regulatory approval
works faster in the European Union than in the United
States. Further, Hwang et al.,24 who analysed the regu-
latory delays for major innovations (e.g. cardiovascular
devices), found that, on average, the delay, defined as
median time difference between European Union
approval marking and the United States approval, is up
to 36.3 months in the case of the United States’ appro-
val. Academic literature suggests that, compared with
20. J.H. Barton, J.E. Ezekie, ‘The Patents-based Pharmaceutical Develop-
ment Process’, 294 JAMA, at 2076 (2005).
21. J.A. DiMasi, H.G. Grabowski, R.W. Hansen, ‘Innovation in the Pharma-
ceutical Industry: New Estimates of R&D Costs’, 47 Journal of Health
Economics, 20-33 (2016).
22. J. Wilkinson. EU Regulatory System Brings Europeans Fastest Access to
Medical Technology Without Compromising Safety. Eucomed press
release (28 January 2011); D. Cohen & M. Billingsley, European are left
to their own devices, BMJ 2011; 342:d2748 doi: 10.1136/bmj.d2748
(Published 14 May 2011)
23. A. Migliore. ‘On the New Regulation of Medical Devices’, 14 Expert
Review of Medical Devices, at 921-3 (2017).
24. T.J. Hwang, E. Sokolov E. et al, ‘Comparison Rates of Safety Issues and
Reporting Trial Outcomes for Medical Devices Approved in the Europe-
an Union and United States: Cohort Study’, 353 BMJ, at i3323 (2016).
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the Japanese market, medical devices in the European
Union are available around five years ahead.25
3 Existing Regulatory
Framework for Medical
Devices
Regulation of medical drugs and devices involves the
competing goals of assuring safety and efficacy while
providing rapid movement of innovative products.
There are several components of the European regulato-
ry framework that are common to the countries manu-
facturing the vast majority of medical devices in use
today (e.g. Australia, Canada, Japan, the United States
and the European Union). These components comprise,
at a minimum,26 regulatory rules; a government-
approved regulatory authority (to enforce the rules); one
or more conformity assessment bodies (which are
accredited by a European Union Member State and
which may issue market approval) to assess whether a
manufacturer or a device conforms to regulatory
requirements; a classification scheme that ranks devices
by level of potential risk associated with their use; a
quality assurance or management system to ensure com-
pliance of a device with quality standards and norms; a
system for evaluating the clinical safety and perform-
ance of a device; a system for granting marketing (mar-
ket entrance) approval for a device that complies with
the regulatory rules; and a surveillance system capable
of detecting and investigating adverse events associated
with the actual use of a device on the market. These ele-
ments will now be explained further.
The European Union regulatory system for medical
devices is quite young; it is twenty-five years behind the
regulation of medical devices in the United States and
about twenty-five years behind the European regulation
of pharmaceuticals. Factors evidenced before, including
differences in the type of industry, the profile for the
products, the risk assessments of the products and the
approach to generating efficacy and effectiveness data,
reflect the difference in regulations for the devices com-
pared with pharmaceuticals: while methods and
research protocols for drug safety had been internation-
ally agreed for around twenty-five years, standards,
essential requirements, consensus protocols for clinical
investigations and common technical specification for
medical devices’ approval emerged only recently. Yet
some components of certain medical devices might be
covered by pharmaceutical regulation.
25. J.P. Boutrand, EU Medical Device Regulatory Framework: Practical
Impact of New Regulations, NAMSA White Paper, available at: https://
www.namsa.com/wp-content/uploads/2015/10/WP-EU-Medical-
Device-Regulatory-Framework.pdf (last visited 13 April 2019).
26. World Health Organization, Medical Device Regulations: Global Over-
view and Guiding Principles (2003), available at: http://www.who.int/
medical_devices/publications/en/MD_Regulations.pdf (last visited
10 April 2019).
Unlike in the case of the United States, which relies on
a strictly centralised process through one agency, the
FDA, the European medical devices’ regulatory frame-
work is synchronised with the regulations of the twenty-
eight national European Union Members who have con-
siderable discretion in how they enforce compliance
with European Law.27 Another key difference between
these systems is that in the United States, the FDA
oversees all regulation of devices. In contrast, the Euro-
pean system confers significant authority on a govern-
mental body and private bodies to oversee device evalu-
ation, market approval and post-market surveillance.
For this reason, Chowdhury28 defines the European
Medical Device regulatory framework as a ‘multilevel
regulation’, in which all the critical aspects of the regu-
latory life cycle are dispersed across multiple adminis-
trative and territorial levels and among both public and
private actors.
The formal regulation of devices in Europe began only
in the mid-1990s and followed the ‘New Approach’ con-
cept, introduced for most consumer goods by the Euro-
pean Commission in 1986. This approach is based on
the concept of a minimum set of mandatory essential
requirements for safety and performance for a product
to be sold in the European Union. The approach does
not prescribe detailed technical specifications or
solutions but promotes the use of voluntary standards
(known as ‘harmonised standards’) that are developed
by recognised standards organisations. Products in com-
pliance with harmonised standards benefit from a pre-
sumption of conformity and can therefore be marketed
throughout the whole European Union area.
Following the new approach, medical devices within
Europe have been regulated by means of three direc-
tives, namely Directive 90/385/ECC concerning the
Active Implantable Medical Devices (AIMDD), Direc-
tive 93/42/ECC concerning Medical Devices (MDD)
and Directive 98/79/ECC concerning In Vitro Diag-
nostic Medical Devices (IVDD).29
The choice of a directive rather than a regulation as a
legal instrument for the regulation of medical devices in
Europe denotes that, unlike in the pharmaceutical sec-
tor, which is subject to regulations, medical devices have
a lower level of harmonisation, since the provisions of
the directives have to be written into national law of
each Member State. Over the past few years, the system
has been subject to amendments and has been comple-
mented by standards and several non-binding technical
guidance documents, reflecting the consensus of stake-
holders regarding the implementation of the directives.
In Europe, governmental regulatory authorities (herein-
after ‘Competent Authority’) and conformity assess-
27. C. Altenstetter, ‘EU and Member State Medical Devices Regulation’, 19
International Journal of Technology Assessment in Health Care, 228-48
(2003).
28. N. Chowdhury, European Regulation of Medical Devices and Pharma-
ceuticals (2014), at 109.
29. Except where otherwise stated, this article focuses on the Medical Devi-
ces Directive No, 93/42/ECC, as it is the most comprehensive of the
three.
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ment bodies (hereinafter ‘Notified Body [ies]’) are key
players within the medical devices regulatory cycle, each
having different responsibilities. Each Member State
has its own Competent Authority who acts on behalf of
the government to ensure that the requirements of the
Medical Device Directives are transposed into the
national law of that country. Each Competent Authority
is also responsible for the designation and supervision of
the conformity assessment bodies, as well as for post-
market surveillance, including the report of adverse
incidents of medical devices. Besides the responsibilities
cited in rule-making, the Competent Authority also has
responsibilities for the approval and monitoring of clini-
cal trials.30
Typically, these competences are delegated to bodies
such us Ministries of Heath, for instance in Italy,31 or an
agency within the Ministry, as in the United
Kingdom,32 Germany33 and France.34 Despite their
being competencies limited to the jurisdiction of the
country where these authorities have been created,
Competent Authorities participate actively in rule-mak-
ing activities (e.g. guidance documents) at the European
level as well.
Conformity assessment bodies, or so-called notified
bodies, are certification organisations tasked with the
enforcement of rules; most of them are privately owned
and run commercial organisations. Notified bodies are
designated and supervised by a European Union coun-
try’s Competent Authority to assess the conformity of
medical devices before being placed on the market.
Their primary function is to carry out tasks related to
conformity assessment procedures set out in the appli-
cable legislation, which are aimed at demonstrating that
the device complies with the requirements of the direc-
tive. They are, furthermore, responsible for suspending
or withdrawing conformity certificates when they find
that a device no longer satisfies the essential require-
ments set forth in the directives.
The European Commission, through the New
Approach Notified and Designated Organisations web-
site (hereinafter ‘NANDO’), maintains an up-to-date
list of bodies notified by European Union Member
States and makes the necessary information available to
all interested parties.
Manufacturers seeking approval to place a medical
device in the European Union market are free to choose
any notified body operating within the European Union,
since there is no territorial linkage between the manu-
facturing site and the location of the notified body. This
means that the manufacturer shares a contractual rela-
tionship with the notified body in which the former
30. D.B. Jefferys, ‘The Regulation of Medical Devices and the Role of the
Medical Devices Agency’, 52 British Journal of Clinical Pharmacology,
229-35 (2001).
31. Ministero della Salute – Direzione generale dei dispositivi medici e del
servizio farmaceutico.
32. Medicines and Healthcare Products Regulatory Agency.
33. Bunsdesinstitut für Artzneimittel und Medizinprodukte.
34. L’Agence Nationale de Sécurité du Médicament et des Produits de
Santé.
chooses the latter to undertake assessment. Critics have
argued that a commercial relationship of this kind may
compromise public interest.35 It is noteworthy that a
substantial share of literature shows that although the
assessment procedures are the same de jure, there are
some variations de facto regarding how notified bodies
implement them,36 as well as in the way notified bodies
are designated and monitored by the relevant Compe-
tent Authorities. These disharmonies have resulted in
widely differing quality in the performance of existing
notified bodies.37
Fundamental to the regulation of medical devices in the
European Union is the use of a classification scheme to
determine the level of control over a device. The classi-
fication of the device dictates the appropriate conformi-
ty assessment procedure: the higher the classification,
the greater the level of assessment required by the noti-
fied bodies. This graduation is justified by the fact that
medical devices cover wide-ranging products and it is
more feasible and economically appropriate to categorise
them rather than to subject all to the same rigorous con-
formity assessment procedure.38 Similar schemes are
utilised in the United States and other developed coun-
tries; however, while the United States has three classes
of devices, the European Union and Japan use a four-
class scheme.39 More precisely, medical devices in
Europe are divided nominatively into three classes, but
class II is divided into IIa and IIb with different require-
ments for each, so that, in essence, the European Union
has four classes.
This classification system considers the extent of human
vulnerability to a device, as well as criteria concerning
the time of uninterrupted contact of the device with the
body and the degree of invasiveness.40 Class I medical
devices pose low risks associated with their use; manu-
facturers of these devices may declare to the Competent
Authority conformity to the marketing requirements
without a need to involve a notified body in this declara-
tion. However, they must maintain a prescribed set of
technical documentation available for inspection. This
assessment procedure is known as ‘self-declaration’ or
‘self-certification’ and is described in Annex VII, Mod-
35. It has been contended that the ‘individual Notified Bodies will be under
commercial pressures to not be perceived as more “difficult” than
others’ and this may lead to a race towards dilution of oversight.
P. Feldschreiber, T. Robinson, PIP and Hips. Do We Need a New Regu-
latory System for Medical Devices? Lexology (25 July 2012), available
at: https://www.lexology.com/library/detail.aspx?g=1e97243d-fb34-
4208-8ecd-86456742fcfd (last visited 18 April 2019).
36. I.C. Santos, G.S. Gazelle, L.A. Rocha, J.M. Tavares, ‘Medical Device
Specificities: Opportunities for a Dedicated Product Development Meth-
odology’, 9 Expert Review of Medical Devices, 299-311 (2014).
37. European Commission, DG Health and Food Safety, DG (Sante)
2017-6255, Overview Report Joint Assessment of Notified Bodies des-
ignated under the Medical Devices Directives (2017).
38. E. French-Mowat, B. Joanne, How Are Medical Devices Regulated in
the European Union?. 105 Journal of the Royal Society of Medicine,
S22-8 (2012).
39. Altenstetter, above n. 6.
40. L.R. Horton, ‘Medical Device Regulation in the European Union’, 50
Food & Drug Law Journal, at 461 (1995).
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ule A, EC Declaration of Conformity of the Medical
Device Directive.41
Approval for more complex devices (classes IIa to III) is
directly handled by notified bodies; nevertheless, while
the marketing of a class IIa device requires verification
only at the production stage, class IIb and III devices are
high-risk devices for which the notified body’s verifica-
tion is necessary at both the design and the production
stages.
In any case, the conformity assessment procedure for
devices falling in classes IIa and IIb requires a Full
Quality Assurance System (QA), which must comprise
the assessment by a notified body of the technical docu-
mentation for at least one sample of the device, includ-
ing the audit of the quality system through the inspec-
tion of manufacturers’ premises and, when justified, the
premises of suppliers and subcontractor.
Class III medical devices must meet the additional
requirement of submitting the design dossier to the
notified body for approval under audit of the Full Qual-
ity Assurance System (Annex II),42 and the device must
undergo clinical investigations to prove safety as a con-
dition for approval. When clinical trials are involved,
the ethics committee must be consulted. After the opin-
ion of an ethics committee has been declared, and at
least sixty days before an investigation begins, manufac-
turers may begin the studies unless notified to the con-
trary. An annex to the directive contains general
requirements for clinical investigations, including
requirements for preclinical safety evaluation and pro-
tection of human subjects.
It should be noted that, although clinical data are
required for high-risk devices, the evidence require-
ments are vague, not available to the public and non-
binding for manufacturers. Generally, clinical trial is
unnecessary for a device that utilises an accepted tech-
nology to manage a medical condition for which the
technology is an accepted indication of use. For
instance, for manufacturers claiming similarity to an
existing product, a comparative literature review typi-
cally suffices.43
The directives call upon the manufacturers, notified
bodies and Competent Authorities to exchange infor-
mation concerning medical device safety; for this pur-
pose the establishment of a European Databank on
Medical Devices (hereinafter ‘EUDAMED’) has been
provided for since 1998. This database stores infor-
mation on manufacturers, data related to approvals and
clinical studies and details on post-market events.
Despite the good purpose, the utility of EUDAMED
has been criticised because so far it has been accessible
only to national and European Union authorities; but
not to the public.44
41. Directive 2001/83/EC, above n. 16.
42. J. Chai, ‘Regulation of Medical Devices in the European Union’, 21
Journal of Legal Medicine, at 537 (2000).
43. C. Sorenson, M. Drummond, ‘Improving Medical Device Regulation:
The United States and Europe in Perspective’, 92 Milbank Quarterly, at
114-50 (2014).
44. Altenstetter, above n. 27.
When determining whether devices comply with the
essential requirements set forth in the directive, notified
bodies are expected to rely on national voluntary stand-
ards adopted pursuant to the so-called harmonised
standards.45 The standards are voluntary, and manufac-
turers, users, certification bodies, public authorities and
healthcare professionals participate in their elaboration;
many are subsequently adopted or incorporated into
international standards by the International Standards
Organization (ISO) or included in the so-called guid-
ance documents (hereinafter ‘MEDDEV’) generated by
the European Medical Device Expert Group convened
by the European Commission. Notwithstanding their
voluntary character, the European Union Medical Devi-
ces Directive46 offers a powerful incentive for manufac-
turers to comply with these standards by providing that
Member States must presume that devices that conform
to standards adopted pursuant to the harmonised stand-
ards the references to which have been published in the
Official Journal of the European Communities comply
with essential requirements.47
A device that meets all the foregoing provisions of the
relevant legislation is granted the conformity mark in
one Member State. It consists of the initials ‘CE’, which
stand for ‘Conformité Européen’. This mark means,
among others, that the device can be freely marketed in
all the other European Member States and the Europe-
an Economic Area (EEA) without further controls and
no further evaluations. Thus, if, for instance, a German
notified body approves the device, then the manufactur-
er can market it immediately in France, Italy and any
other European Union country. This is significantly dif-
ferent from the position for medicinal products, for
which market approval is needed in each Member State
unless the centralised approval through the European
Medicine Agency (EMA) is available.
In the post-marketing phase, manufacturers are
required to report all serious adverse events to the Com-
petent Authorities; all that information is further colla-
ted into the EUDAMED database. The post-market
surveillance comprises both active monitoring of medi-
cal devices during their use and the notification to Com-
petent Authorities of those situations that led or have
led to serious injury of a patient, user or other person,
death of a patient, user or other person; severe deterio-
ration of the state of health of a patient, user or other
person; or significant damage of the device. Reporting
was voluntary from 1998 until 2011, when it became
mandatory for manufacturers to directly report adverse
events.
45. R.F. Kingham, ‘Regulation of Medical Devices in the European Com-
munity’, 47 Food & Drug Law Journal, at 563 (1992).
46. Art. 5, Directive 2001/83/EC, above n. 16.
47. Horton, above n. 40.
171
Magali Contardi doi: 10.5553/ELR.000139 - ELR November 2019 | No. 2
4 Political Landscape and the
Need for Revision
While there are agreed European standards for medical
devices, the previous decades have witnessed rising con-
cerns that these standards are not uniformly applied.48
In the British Medical Journal, Freemantle49 asserted
that the current European Union regulatory framework
was inadequate to provide enough safeguards for tech-
nologies that affect morbidity, mortality and health-
related quality of life. Eikermann et al.50 reached similar
conclusions, by highlighting safety issues related to the
market authorisation pathway and the need for a more
transparent, evidence-based process for medical device
approval. Furthermore, as evidenced before, the lack of
uniformity in the designation and monitoring of notified
bodies among the Competent Authorities has been iden-
tified by various scholars as one of the prime reasons for
the widely differing quality in the performance of noti-
fied bodies.51 Such segmentation has undoubtedly led to
different levels of health and safety protection and has
created obstacles to the internal market.
At the same time, efforts towards harmonisation have
been hampered by uncertainties due to regulatory gaps
derived from new medical device technology that has
been developed in the past years. As Dr. Redberg
explains:
In the past 10-20 years the number and complexity of
medical devices has exploded … in contrast to most
devices in the 1970s, the newer products pose sub-
stantially greater risks – even life-threatening risks –
to patients. For example, many new medical devices
are permanently implanted in a patient’s body and
can be moved or changed, if at all, only with great
risk to the patient.52
In this regard, it is interesting to note that while medical
devices historically included software applications with
algorithmic calculations and automated functionality,
which capabilities resided within the physical medical
device, modern software-based medical devices increas-
ingly integrate artificial intelligence (hereinafter ‘AI’),53
48. D. Cohen, M. Billingsley, ‘Europeans Are Left to Their Own Devices’,
342 BMJ, at d2748 (2011).
49. N. Freemantle, ‘Evaluating and Regulating the Device Industry’, 342
BMJ, at d2839 (2011).
50. M. Eikermann, C. Gludd, M. Perleth, C. Wild, S. Sauerland, I. Gutierrez-
Ibarluzea, S.-L. Antoine, J. Demotes-Mainard, E.A.M. Neugebaue,
‘Commentary: Europe Needs a Central, Transparent, and Evidence-
based Regulation Process for Devices’, 346 BMJ, at f2771 (2013).
51. Santos et al., above n. 36.
52. R.F. Redberg, Testimony to Subcommittee on Health, House Commit-
tee on Energy and Commerce (17 February 2011), available at: https://
it.scribd.com/document/325129078/HOUSE-HEARING-112TH-
CONGRESS-IMPACT-OF-MEDICAL-DEVICE-REGULATION-ON-JOBS-
AND-PATIENTS (last visited 19 April 2019).
53. S. Kumba, AI in Medical Devices – Three Emerging Industry Applica-
tions, Business Intelligence and Analytics (2019), available at: https://
emerj.com/ai-sector-overviews/ai-medical-devices-three-emerging-
industry-applications/ (last visited 19 April 2019).
making it possible to reveal patterns in patient records,
scanned images or even data stored in mobile phones to
improve diagnosis of patients, assist in their treatment
and even change something about a medical device
without human interaction or by recommending some
action to a human recipient who then interacts with the
medical device to accept or reject the recommendation.
Similarly, wearables and other medical devices pro-
duced by general product manufacturers and mobile
application (known as ‘app’) developers have become
tremendously popular. These advances, however, chal-
lenge the legally defined concepts of a medical device
and the associated boundaries of regulation.54
Underlining the need to consolidate and simplify the
regulatory framework, promote its uniform interpreta-
tion across Member States and fill in the regulatory gaps
that emerged with regard to a number of new technolo-
gies, the Commission initiated in 2008 a fundamental
revision of the three Medical Device Directives.55
To this end, the Commission conducted two public
consultations – one in 2008 and the second one in
2010 – seeking input from industry members, regulato-
ry authorities, professionals and other stakeholders
regarding the regulatory system and possible targets for
reform. A process for reviewing the medical devices reg-
ulatory legislation followed the aforementioned consul-
tations, which was expected to conclude with the draft
of the proposals for reform by the beginning of 2012.
In the meantime, two high-profile incidents that occur-
red between 2010 and 2012 prompted the Commission
to push for the replacement of the former, less restric-
tive European Union Medical Device Directive with a
more stringent system.56
In 2010, metal-on-metal (hereinafter ‘MoM’) hip
replacements were recalled because of high failures
rates; these implants were originally designed as an
alternative in younger osteoarthritis patients, for whom
long-term total hip replacement device survival is poor.
However, MoM protheses have raised concerns about
the release into the body of metals such cobalt and chro-
mium and entry into the bloodstream and soft tissues.57
The problem caught the attention of the European
Union, where around 100,000 patients have been sub-
jected to MoM hip replacement. Investigations showed
that 650 patients were fitted with hip protheses with
modifications that had not been approved in the Euro-
pean Union.58
54. C.A. Tschider, ‘Deus Ex Machina: Regulating Cybersecurity and Artificial
Intelligence for Patients of the Future’, 5 Savannah Law Review, at 177
(2018).
55. European Commission Directorate for Health and Consumers, Revision
of the Medical Device Directives (26 October 2013), available at:
www.ec.europa.eu/health/medical-devices/documents/revision/
index_en.htm (last visited 20 January 2019).
56. European Commission Press Release, Medical Devices: European Com-
mission Calls for Immediate Actions – Tighten Controls, Increase Sur-
veillance, Restore Confidence, available at: http://europa.eu/rapid/
press-release_IP-12-119_en.htm (last visited 20 January 2019).
57. D. Cohen, How Safe Are Metal-on-metal Hip Implants? 344 BMJ, at
e1410 (2012).
58. D. Cohen, ‘Faulty Hip Implant Shows up Failings of EU Regulation’, 345
BMJ, at e7163 (2012).
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Similarly, since 2010, potential health concerns have
been raised in regard to silicone breast implants manu-
factured by the French firm Poly Implant Prostheses
(hereinafter ‘PIP’). In 2012 an unexpectedly large num-
ber of women were diagnosed as suffering from rup-
tured breast implants, leading to the breast implant con-
troversy. The controversy turned into a scandal as PIP
has been manufacturing implants using industrial grade
silicone. The French government called the women who
had received this implant for recall at no cost, but
because of poor record keeping women were unable to
find out whether they had received these implants or
not.
These separate incidents, besides having highlighted the
need for strengthening of the European Union Medical
Devices Directives, led to a debate on the need for
actions to enhance the traceability and long-term moni-
toring of devices in terms of safety and performance. In
a resolution adopted in June 2012,59 the European Par-
liament called for a more stringent surveillance, placing
on the market requirements and safety controls, a stron-
ger vigilance system as well as better patient information
about the quality of high-risk, implantable devices and
the potential risks.
In September 2012 the European Commission finally
adopted a proposal60 for Regulation on Medical Devices
and In-Vitro Diagnostics and submitted the draft for
approval to the European Parliament and the Council,
which introduced several changes in 2014 and 2015,
respectively.61 The final text of the two regulations was
agreed in 2016 and, after being translated into the offi-
cial European Union languages, both texts were finally
adopted in April 2017. The process concluded with the
publication in the Official Journal of the European
Union in May 201762,63; both regulations became legally
binding on 25 May 2017.
59. European Parliament Resolution on Defective Silicone Gel Breast
Implants Made by French Company PIP, https://publications.
europa.eu/en/publication-detail/-/publication/1b63129f-4e29-11e3-
ae03-01aa75ed71a1/language-en (last visited 25 January 2019).
60. Commission Proposal for a Regulation of the European Parliament and
the of the Council on Medical Devices and Amending Directive
2001/83/EC, Regulation (EC) No. 178/2001 and Regulation (EC) No.
1223/2009, COM(2012) 542; Commission Proposal for a Regulation of
the European Parliament and of the Council on In Vitro Diagnostic
Medical Devices, COM(2012) 541.
61. L. Hancher, M.E. Földes, ‘Revision of the Regulatory Framework for
Medical Devices in the European Union: The Legal Challenges’, 4 Euro-
pean Journal of Risk Regulation, 429-35 (2013).
62. Regulation European Union 2017/745 on Medical Devices of the Euro-
pean Parliament and of the Council of 5 April 2017. Official Journal of
the European Communities No. L-117/1 (2017).
63. Regulation European Union 2017/746 on in vitro diagnostic medical
devices and repealing Directive 98/79/EC and Commission Decision
2010/227/EU of the European Parliament and of the Council of 5 April
2017. Official Journal of the European Communities No. L-117/176
(2017).
5 New Regulations for Medical
Devices: Main Changes
The new regulations promise to introduce a series of
extremely important improvements to modernise the
current system and to properly address the gaps of the
past.
The proposals take the form of a Regulation; unlike
directives, which need transposition by national parlia-
ments, regulations are directly enforceable, and stake-
holders are accountable under European Union law. It is
believed to be the appropriate legal instrument as it
imposes clear and detailed rules that will become appli-
cable in a uniform manner at the same time throughout
the European Union. Furthermore, since for historical
reasons the Active Implantable Device Directive and the
Medical Device Directive were regulated in two sepa-
rate legal instruments, in the interest of simplification,
these two directives have been replaced by a single legis-
lative act applicable to all medical devices other than in
vitro diagnostic.64
Although the new regulations are already legally bind-
ing, they will apply three years65 after publication in the
case of Medical Device Regulation and five years66 after
publication in the case of In Vitro Diagnostic Device
Regulation. This transition period is meant to allow all
major stakeholders, including the European Union
Commission, Competent Authorities, notified bodies
and manufacturers, to meet their respective obligations
from the date of application.
While under the new Regulation the classification
scheme into four classes has been retained, rules have
tightened and changed for some products, and, as a
result, some devices will be reclassified to higher
classes.67 For the purpose of the product’s classification,
the criterion is still the vulnerability of the human body,
although the potential risk associated with the technical
design and manufacture of the device will also be taken
into account.68 In addition, some devices lacking medi-
cal purpose that were previously exempt from the regu-
lations but that present a high-risk profile are now with-
in the scope of the new legislation.69
Interestingly, while the definition of medical devices in
the Regulation essentially maintains the legacy of the
previous legislation, the ‘intended purpose’ under the
new medical device definition has been broadened to
64. Recital 5, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
65. The Medical Device Regulation will apply as of May 2020.
66. The In Vitro Diagnostic Device Regulation will apply as of May 2022.
67. For instance, active implantable devices and their accessories, devices
incorporating nanomaterials, some software devices as well as devices
intended specifically for use in direct contact with the heart or central
circulatory system will be classified as Class III.
68. Recital 58, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
69. For instance, it includes aesthetic devices that may not have a medically
intended purpose (coloured or non-corrective contact lenses) as well as
devices designed for the purpose of ‘prediction’ of a disease or other
health condition. Arts. 1 and 2 Medical Device Regulation, above n. 62.
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include ‘prediction’ and ‘prognosis’ of disease and other
health conditions. This may bring certain digital health-
care technologies70 under the scope of this definition.
The substantive requirements and conformity assess-
ment procedures are more complex and burdensome
under the Medical Device Regulation. For instance, the
revised text demands more rigorous clinical evidence for
class III and implantable medical devices. With only
certain exceptions, these categories of devices must go
through clinical investigations; equivalence principles as
compliance with current MEDDEVs guiding docu-
ments on clinical requirements71 will in many cases be
insufficient to comply with the new rules. In particular,
manufacturers will therefore need to conduct clinical
investigations72 in case they lack sufficient clinical evi-
dence to support the claims done on both safety and
performance of a dedicated device,73 ‘sufficient clinical
evidence’ being only clinical data produced either by the
manufacturer on its own or by the competitor, although
in this latter case a contract must be available to justify
access to the clinical data. Essentially, under the new
Regulation full access to clinical data used to support
the safety and performance claim is mandatory in order
to satisfy the clinical investigation’s requirement.
In line with it, the clinical evaluation procedure for cer-
tain high-risk profile devices will need to be carried out
under the ‘scrutiny’ of a newly formed Committee
Medical Devices Coordination Group (hereinafter
‘MDCG’) made up of members appointed by Member
States due to their role and experience in the field of
medical devices, who will assess the preliminary report
of the notified bodies and will eventually review it
before granting the ‘CE’ certification mark.74 Justified
by the need to harmonise evaluation of high-risk devices
on clinical aspects to solve problems experienced in the
past, this scrutiny mechanism empowers the authorities
to have a ‘second look’ at individual assessments and
make their views known before a device is placed on the
market.
The forthcoming changes will undoubtedly represent a
huge challenge for manufacturers; however, they might
also act as a trigger for implementing an operationalised
approach while ensuring consistent high standards. As
Altenstetter expressed,
The twenty-year-old system has relied on manufac-
turers’ claims of the performance of high-risk medi-
cal devices, but with little input from clinical practi-
tioners and academic scientists. Hence it makes a
great deal of sense to give more considerations to
70. For instance, digital health apps.
71. Guidance document MEDDEV 2.7/1 Rev.4 on Clinical Evaluation
Reports (CER) for Medical Devices, European Commission, DG Internal
market, Industry, Entrepreneurship and SMEs.
72. Clinical investigations refer to a systematic investigation involving one
or more human subjects, undertaken to assess the safety or perform-
ance of a medical device.
73. Art. 49, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
74. Arts. 78 and 80, Regulation European Union 2017/745 on Medical
Devices, above n. 62.
clinical data, clinical assessments, and make use of
clinicians’ experience with patient outcomes.75
Nevertheless, (probably) in response to the stakehold-
ers’ constant requests of rendering the application of the
MDR to legacy products more viable, one step back to
the older approach has been taken in this regard.
Indeed, on 22 March 2019 the MDCG published a
document on the interpretation of Article 54(2)b of the
Medical Devices Regulation, which states:
The Clinical evaluation consultation procedure shall
not be required where the device has been designed
by modifying a device already marketed by the same
manufacturer for the same intended purpose, pro-
vided that the manufacturer has demonstrated to the
satisfaction of the notified body that the modifica-
tions do not adversely affect the benefit-risk ratio of
the device.76
In addition, a post-market clinical follow-up evaluation
report (PMCF) and summary of safety and clinical per-
formance is required to be updated annually for class III
devices and class IIb implantable devices and at least
every two years for class IIa and class IIb non-implanta-
ble devices to facilitate the gathering of quality, per-
formance and safety data throughout the device’s life-
time. This requirement raised some concerns among
stakeholders, who prima facie construed this rule as
requiring annual clinical data – in line with the MED-
DEV guidance documents applicable in the context of
the medical device’s directives, namely, as requiring
further clinical investigations. Nevertheless, it is worth
noting that under the Regulation the definition of
PMCF is broad and relates to all types of clinical infor-
mation, namely vigilance, complaints, technical infor-
mation and publicly available information; by contrast,
clinical follow-up under the umbrella of the directives is
very much focused on clinical studies and clinical data.77
To enhance transparency within the system, the sum-
mary of safety and clinical performance shall be made
available via EUDAMED, to which access will now be
extended to notified bodies, the MDCG, economic
operators (manufacturers, authorised representatives,
importers, sponsors), experts and the public, including
medical institutions.78 The inclusion of data sourced
from clinical investigations will become mandatory for
new class III or implantable medical devices; the details
of these clinical investigations will be stored in a system
75. C. Altenstetter, ‘US Perspectives on the EU Medical Device Approval
System, and Lessons Learned from the United States’, 4 European Jour-
nal of Risk Regulation, at 443 (2013).
76. Interpretation of Art. 54(2)b of 22 March 2019, Medical Device Coordi-
nation Group.
77. Indeed, the notion of PMCF was first introduced in the guidance docu-
ment on post-market clinical follow-up studies MEDDEV 2.12 rev 2.
78. Arts. 26 and 27, Regulation European Union 2017/745 on Medical
Devices, above n. 62.
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that is interoperable with the clinical trial database for
medicinal products.79
In the past, lack of data management has been perceived
as a major obstacle to reaching final recommendations
on the use of medical devices; and having the chance to
access clinical investigation data will facilitate post-mar-
ket analysis and will give more transparency to the
system.80 Likewise, the aforementioned centralising
measures such as the creation of the Medical Device
Co-ordination Group, a central database and more
stringent clinical trials seem to demonstrate the legisla-
ture’s intention towards a medical device’s authorisation
and monitoring system similar to that currently apply-
ing to pharmaceuticals in Europe.
The forthcoming Medical Device Regulation places fur-
ther responsibilities on the notified bodies, which will
be empowered to carry out unannounced inspections of
manufacturers and their sub-contractors’ sites to check
whether they are complying with quality management
systems, alongside physical or laboratory tests on devi-
ces. Supervision of notified bodies will also change con-
siderably, starting with the requirements that Compe-
tent Authorities must apply for a new designation81;
notified bodies will also be under heightened scrutiny
from Competent Authorities as well as under joint
assessment with experts nominated by Member States
and the Commission.82 The proposal also requires rota-
tion of the notified body’s personnel involved in the
assessment of medical devices at appropriate intervals to
strike a reasonable balance between the knowledge and
experience required to carry out thorough assessments.
Stakeholders83 claim that while all these new measures
will ensure a more rigorous oversight and uniform per-
formance of the assessment procedures, they might also
result in a shortfall of resources owing to the reduction
in the number of notified bodies that are going to be re-
notified. This argument is further supported by the
information already available on NANDO, the Europe-
an Union’s notified body database, according to which
the number of notified bodies has dropped from about
eighty to fifty-nine.84 A possible shortfall is especially
worrisome in the in vitro devices’ arena, where about
80% of products – an estimated 35,200 – will require
notified body oversight for the first time. Interestingly,
even under the umbrella of the implementation of the
current legislative framework, administrative capacities
varied greatly across Member States, most of whom
79. S. Milmo, ‘New Regulations for Combination Products’, 28 Pharma-
ceutical Technology Europe (2016).
80. Migliore, above n. 23.
81. Art. 29, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
82. Art. 35, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
83. Medtech Europe, Implementing the New MD and IVD Regulations:
Industry Calls for Solutions to Ensure Continuity of Care to Patients
(2018), available at: https://www.medtecheurope.org/wp-content/
uploads/2018/07/
MTE_PolicyPaper_MDRIVDRImplementationCallforSolutions_July2018.
pdf (last visited 11 April 2019).
84. This number refer to the information available by December 2018.
were unable to provide enough skilled manpower
capacity for enforcing compliance with the directives.85
The revised regulatory framework further includes the
introduction of a Unique Device Identification System
(hereinafter ‘UDI’),86 consisting of a series of numerals
of an alphanumeric identification code, which will need
to be displayed on every medical device to allow the
unambiguous identification of a specific device on the
market.
The complexity of the UDI system is reflected in the
multiple regulatory requirements that it encompasses; it
also imposes obligations on all actors of the supply
chain, from manufacturers to healthcare professionals,
with the involvement of notified bodies and Competent
Authorities. The intended result is to improve the trace-
ability of devices throughout the supply chain and
thereby help the authorities and manufacturers to take
prompt and appropriate actions in response to concerns
about device safety.
From a labelling approach, the UDI contains a device
identifier (known as ‘UDI-DI’), which is an identifier of
a device model and is also used as the ‘access key’ to
information stored in the UDI database, such as certifi-
cates, declaration of conformity, technical documenta-
tion and summary of safety and clinical performance.
Furthermore, it comprises a production identifier
(known as ‘UDI-PI’) that identifies the unit of device
production. The UDI shall, in addition, be used for
reporting serious incidents, and, to support this effort,
all the information will be channelled and publicly avail-
able via EUDAMED. All stakeholders shall be able to
obtain information on the clinical safety performance of
a targeted medical device and to track who supplied a
medical device and to whom. This is likely to enhance
the effectiveness of post-market safety-related activities,
in line with the objectives pursued by the reform.
The UDI requirements described in the Medical
Device Regulation are completely new for the European
Union market – since the Medical Device Directive,
which is still in force, has no provisions on the traceabil-
ity of medical devices and follows the global trend in
handling the traceability of medical devices.87 In this
regard, despite the labelling and operational overhaul
that would be required to implement the UDI system,
mostly seen as ‘cost-prohibitive’ and ‘technically chal-
lenging’, it has been reasonably argued88 that a globally
harmonised approach to UDI is critical to realising the
benefits of such a system, is a prerequisite for medical
device traceability in a globalised economy and lays the
groundwork for the worldwide exchange of medical
device data.
85. Altenstetter, above n. 27.
86. Art. 24, Regulation European Union 2017/745 on Medical Devices,
above n. 62.
87. Similarly, in the United States, device manufacturers will be required to
place a UDI on the device’s labels.
88. Global Medical Technology Alliance, Unique Device Identification:
Insights and benefits from a single UDI System in the International Are-
na, White Paper (2018), available at: http://www.globalmedicaltechnol
ogyalliance.org/papers/GMTA%20UDI%20White%20Paper.pdf (last
visited 23 April 2019).
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In conclusion, one thing is clear: a new regulatory
system was necessary to improve the clarity of the regu-
latory requirements and harmonise the application of
regulations across the European Union’s Member
States. However, this may mean a major overhaul of the
European regulatory framework, with the risk that the
tougher requirements for the industry lead to a poten-
tially greater timeline to certification, creating disincen-
tives for bringing new medical technologies to the mar-
ket.89
6 Chief Challenges Resulting
from the Regulatory
Framework: Would an
Extension of the Term of
Patent Protection Be Needed
for Medical Devices to
Promote Medical Device
Innovation?
The World Health Organisation (WHO) defines inno-
vation as a ‘process cycle of three major phases that feed
into each other: discovery, development and delivery’.90
Medical device innovation refers not only to the inven-
tion of new devices but also to adjustments to, or incre-
mental improvements of, existing devices and clinical
practices. In brief, innovation of medical devices must
demonstrate added value for patient health.
On the one hand, the apparent nexus between the patent
system and economic development, which depicts pat-
ents as a lever of industrial progress, has undoubtedly
played a role in innovation incentive theory, becoming
probably the most quoted argument in favour of (medi-
cal device) patents.91 Adopting a patent system is
thought to encourage investment of resources in making
inventions by giving inventors limited monopoly rights
in exchange for public disclosure of their invention. On
the other hand, however, regulatory issues impact on
the whole cycle of the innovation as well. The latter
means that the regulatory framework has to be taken
into account in the early stages of the medical device
design and development, during preclinical and clinical
evaluation, product regulatory evaluation, manufactur-
ing and post-marketing surveillance. For this reason,
the relationship between medical devices developers and
89. J.J. Howard, ‘Balancing Innovation and Medical Device Regulation: The
Case of Modern Metal-on-metal Hip Replacements’, 2016 Medical
Devices, 267-75 (2016).
90. World Health Organization-Intergovernmental Working Group on
Public Health, Innovation and Intellectual Property (IGWG). The Global
Strategy and Plan of Action on Public Health, Innovation and Intellectu-
al Property (GSPOA), (2008/2009).
91. F. Machlup, E. Penrose, ‘The Patent Controversy in the 19th Century’,
X The Journal of Economic History, 1-29 (1950).
the regulatory framework is also critical for innovation
and competitiveness in this sector.92
In this regard, scholars have empirically found that in
relation to pharmaceutical innovations, owing to the
entire regulatory bundle, the effective patent life for
pharmaceutical innovations, that is, the period between
the patent application date and the date when a pharma-
ceutical is put on the market, is significantly reduced;
frequently, at least half the patent term has expired
before a product reaches the market.93
To cope with this issue, some countries have introduced
in their statutes an extension of the patent term by pro-
viding a supplementary term of protection for pharma-
ceutical94 inventions. The balance between the exclusive
right conferred by patents on innovative pharmaceutical
products and the regulatory rules for their marketing
approval seem to have been achieved in certain Europe-
an Union Member States, which started to regulate this
matter independently. Lastly, at the European level pat-
ent-term extension has been introduced by means of a
new title, the Supplementary Certificate Protection
(hereinafter ‘SPCs’),95 to provide a harmonised solution
and to deter pharmaceutical R&D from shifting to non-
European markets, e.g. Japan or the United States.96
No wonder why while much has been written about
extending the patent-term protection in the pharma-
ceutical field, little has been discussed in relation to
SPCs (or analogous title) for medical devices. If the
intended purpose of the introduction of such a patent-
term extension was to compensate the patentee that has
experienced significant regulatory delays in getting its
patented pharmaceutical products into the market, at
the time that the SPCs regulation was introduced, no
lengthy regulatory delays significantly affected medical
devices.97
The gradual expansion of the medical device regulatory
framework has resulted from the complex interaction of
various stakeholders’ interests, driven by the interest or
perspectives of these stakeholders: the industry seeks
legal certainty and transparency, and speed to market
their devices, while patients and the general public seek
access to innovative medical technology at zero risk and
in respect of fully tested efficacious products.
92. K.D. Lind, ‘Implantable Devices: Regulatory Framework and Reform
Options’, 130 AARP Public Policy Institute (2017).
93. A study published by the Intellectual Property Institute on 31 August
2007 showed that by 1990 the European effective patent life for phar-
maceutical products was between ten and twelve years. D. Curley,
Extending Rewards for Innovative Drug Development: A Report on
Supplementary Protection Certificates for Pharmaceutical Products
(2007).
94. United States in 1984, Japan in 1988, Europe during the 1990s, France
and Italy in 1991. T. Rolling, ‘How Europe’s SPC Regime Works in Prac-
tice’, 54 Managing Intellectual Property, at 260 (2016).
95. Council Regulation (EEC) No. 1768/92 of 18 June 1992 concerning the
creation of a supplementary protection certificate for medicinal prod-
ucts, Official Journal of the European Communities No. L 182 (1992),
later updated and replaced by (EC) Regulation No. 469/2009 of the
European Parliament and of the Council of 6 May 2009 concerning the
supplementary protection certificate for medicinal products, Official
Journal of the European Communities No. L 152 (2009).
96. Recitals 6 and 7 of EC Regulation No. 469/2009, Ibid.
97. Migliore, above n. 23.
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Nonetheless, the continued overhaul of the regulatory
framework of medical devices, culminating with the
entry into force of the two new regulations, seems to
lengthen the time needed for placing medical devices on
the market. At the same time, stakeholders have raised
concerns about the more stringent Medical Device Reg-
ulation, claiming that it would ultimately result in late
access to new technologies and would therefore be
linked to human costs. Likewise, some literature con-
tends that regulatory uncertainty leading to longer time-
lines for the approval process for new medical products
may create disincentives for pioneer entry by meaning-
fully increasing the length of the product development
period for novel devices.98
Despite the merits of the forthcoming medical device
regulatory framework, a notable challenge remains that
might hinder medical device innovations in Europe.
Evidenced shifts in the regulatory framework for medi-
cal technology might result in the erosion of the effec-
tive term of patent protection,99 leading to undesired
market failures and barriers to major medical device
innovations.100 As has been evidenced,101 new innova-
tive medical devices are characterised by a large product
heterogeneity and significant uncertainty about the reg-
ulatory process itself. This regulatory uncertainty is
likely to bring some discouragement into medical device
innovation.
At the state of play and by contrast to pharmaceutical
innovations, the SPCs legislation does not expressly
foresee a medical device to be an eligible product for
obtaining an SPC,102 and judicial decisions among the
European Union jurisdictions have been rather reluc-
tant to grant it.103 Sound policy considerations are
urgently needed to optimise the existing European
Medical Device innovation system. Worth mentioning
here is that there is no primary source of law preventing
secondary law from amending the term of protection for
medical devices.104 Nonetheless, for the time being, the
98. R. Guerra-Bretaña, A.L. Flórez-Rendón, ‘Impact of Regulations on Inno-
vation in the Field of Medical Devices’, 34 Research on Biomedical
Engineering, 356-67 (2018).
99. S. Sterckx, Does European Patent Law Unfairly Discriminate Against
Medical Devices as Compared with Pharmaceuticals? 25 Expert Opin-
ion on Therapeutic Patents, 845-8 (2015).
100. E. Klar, ‘Medical Device Regulation als aktuelle Herausforderung für die
rechtssichere Einführung neuer Technologien‘, 2018 Chirurg, 755-9
(2018).
101. A.D. Stern, ‘Innovation under Regulatory Uncertainty: Evidence from
Medical Technology’, 145 Journal of Public Economics, at 181-200
(2017).
102. A. Hutchinson, N. Fischer, P. Schröler, Is There a Future for Medical
Device SPCs? 16 Bio-Science Law Review (2017).
103. Lastly, Court of Justice of the European Union, C-527/2017, Boston
Scientific, ECLI:EU:C:2018:867, http://curia.europa.eu/juris/liste.jsf?
language=en&num=C-527/17 (last visited 1 December 2018).
104. Max Planck Institute For Innovation and Competition, Study on the
Legal Aspects of SPC – Final Report MPILC (2018), available at: https://
ec.europa.eu/docsroom/documents/29524 (last visited 23 April 2019).
105. ‘The scope and sectors covered by the SPC Regulation were decided
over 20 years ago. However, in these two decades many of the under-
lying aspects of the SPC Regulation have changed, among others,
Commission has only timidly introduced this topic on
its table for discussions.105,106
changes in innovation patterns, big data, bio-medicines, personalised
medicines, increasing importance of medical devices as well as changes
in marketing authorisation procedures European Commission’, Europe-
an Commission Call for tender: Study on the economic impact of Sup-
plementary Protection Certificates, pharmaceutical incentives and
rewards in Europe (2017).
106. Commission Staff Working Document, Summary of the replies to the
public consultation on Supplementary Protection Certificates and patent
research exemption for sectors whose products are subject to regulated
market authorisations, SWD(2018) 242 final, available at: https://eur-
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2018:0242:FIN:EN:PDF (last visited 1 December 2018).
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